Payment overview · 2025
General Payments
$1,451.33
93 reported records · 23 companies
Healthcare provider profile · identity verified
Kenneth Nickle, DO
Allopathic & Osteopathic Physicians|Family Medicine · GREENEVILLE, TN · NPI 1790849081
Verified facts
What the public records show
CMS Open Payments records show Kenneth Nickle, DO received $1,451.33 in general payments during 2025 across 93 reported records.
ABBVIE INC. accounted for 14.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $216.44 | 14.9% | 28 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $196.07 | 13.5% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $189.83 | 13.1% | 11 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $145.02 | 10.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $68.70 | 4.7% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.25 | 3.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $56.86 | 3.9% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.50 | 3.9% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.98 | 3.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.18 | 3.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $50.42 | 3.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.42 | 2.8% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.66 | 2.6% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $35.00 | 2.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.83 | 2.4% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.42 | 1.7% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $23.66 | 1.6% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $21.78 | 1.5% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.86 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.37 | 1.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.34 | 1.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $16.32 | 1.1% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $15.42 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,451.33 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $385.90 | 20 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $145.02 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $103.35 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.35 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $95.60 | 19 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $56.86 | 3 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $56.86 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.50 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.23 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $50.42 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.82 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.42 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $37.66 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $35.00 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.42 | 1 | 2025 |
Source payment records
|
|||||
| General - Erectile Dysfunction Normalized: general erectile dysfunction |
Device | Boston Scientific Corporation | $23.66 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.81 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.49 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.43 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $16.32 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.87 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $9.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 15 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 56 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 58 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 349 | 77 |
| Gabapentin | Gabapentin | 315 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 286 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 277 | 67 |
| Omeprazole | Omeprazole | 263 | 66 |
| Alprazolam | Alprazolam | 234 | 37 |
| Montelukast Sodium | Montelukast Sodium | 193 | 40 |
| Furosemide | Furosemide | 190 | 38 |
| Lisinopril | Lisinopril | 175 | 50 |
| Metformin Hcl | Metformin Hcl | 166 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 145 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 144 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 138 | 37 |
| Losartan Potassium | Losartan Potassium | 137 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 131 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 123 | 28 |
| Potassium Chloride | Potassium Chloride | 121 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 118 | 37 |
| Trazodone Hcl | Trazodone Hcl | 114 | 23 |
| Sertraline Hcl | Sertraline Hcl | 112 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 27 |
| Famotidine | Famotidine | 97 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 97 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 22 |
| Buspirone Hcl | Buspirone Hcl | 87 | 21 |
| Prednisone | Prednisone | 87 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 81 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 81 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 15 |
| Clonazepam | Clonazepam | 76 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 73 | 15 |
| Simvastatin | Simvastatin | 72 | 21 |
| Meloxicam | Meloxicam | 71 | 20 |
| Lorazepam | Lorazepam | 70 | 21 |
| Ozempic | Semaglutide | 70 | 13 |
| Tramadol Hcl | Tramadol Hcl | 68 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 12 |
| Allopurinol | Allopurinol | 60 | 16 |
| Jardiance | Empagliflozin | 59 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 14 |
| Linzess | Linaclotide | 58 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 11 |
| Spironolactone | Spironolactone | 57 | 12 |
| Eliquis | Apixaban | 56 | 13 |
| Glimepiride | Glimepiride | 54 | 16 |
| Carvedilol | Carvedilol | 53 | 13 |
| Lamotrigine | Lamotrigine | 51 | suppressed |
| Xarelto | Rivaroxaban | 51 | 14 |
| Pregabalin | Pregabalin | 50 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 12 |
| Celecoxib | Celecoxib | 45 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Promethazine Hcl | Promethazine Hcl | 43 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 43 | suppressed |
| Baclofen | Baclofen | 42 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 13 |
| Glipizide | Glipizide | 40 | suppressed |
| Lansoprazole | Lansoprazole | 40 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Ondansetron Odt | Ondansetron | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Levetiracetam | Levetiracetam | 34 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 16 |
| Mounjaro | Tirzepatide | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 27 |
| Diazepam | Diazepam | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Risperidone | Risperidone | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | 11 |
| Donepezil Hcl | Donepezil Hcl | 28 | suppressed |
| Fluconazole | Fluconazole | 28 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 27 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Water | Water For Irrigation,sterile | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Phenobarbital | Phenobarbital | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Levofloxacin | Levofloxacin | 15 | 11 |
| Nystatin | Nystatin | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Eryped 400 | Erythromycin Ethylsuccinate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Keppra | Levetiracetam | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Prolia | Denosumab | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Acetylcysteine | Acetylcysteine | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Cetirizine Hcl | Cetirizine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,451.33 · 93 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, APTIMA, Auvelity, CAPLYTA, COMIRNATY, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FANAPT, FARXIGA, GVOKE HYPOPEN, General - Erectile Dysfunction, HETLIOZ, Heplisav-B, IBSRELA, INGREZZA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, REXULTI, Rybelsus, THINPREP 2000 PROCESSOR, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, Xhance, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error